Treatment of Ebola Monkeys with only one tablet

According to RCO News Agency, According to a new study published on Friday, Ebola monkeys can be treated with only one pill, and these findings can pave the way for more practical and affordable treatments for humans.

Ebola was first identified in year 6 and is thought to have come from bats. It is a deadly viral disease that spreads through direct contact with the patient’s body fluids and causes severe bleeding and organs.

Since the prevalence of the disease mainly occurs in southern Saharan Africa, pharmaceutical companies lack financial incentives to develop appropriate treatments, and the dispersed nature of the prevalence of the disease has made it difficult for clinical tests.

Only one vaccine for the disease is widely confirmed in year 6, and while two intravenous antibodies improve the results, they need to be maintained in costly refrigerators and are difficult to prescribe some of the poorest areas in the world.

Thomas Geisbert, a virgin at the University of Texas Medical Branch in Galoston, which led the new study in Science Advances, says: “We are really trying to provide a more practical option to use, control and control the outbreak.”

Gizbert and his colleagues tested an antiviral Obeldesivir drug, which is an intravenous venous Remdesivir form and was originally made to treat Cuvid-1.

Abdulzizir is a “polymerase inhibitor”, meaning it blocks an enzyme that is critical to the virus reproduction.

The researchers contaminated the roseus and synomulgus macakers with a high dose of the Ebola virus type. One day after exposure to the virus, the monkeys received an abdelzizir tablet daily for 5 days, while the other three monkeys as the control group received no cure and lost their lives.

Abdulzizir protected 2 % of synomulgus macacons and 2 percent of roseus macacons that are biologically closer to humans.

The drug not only removed the virus from the blood of the monkeys treated, but it also created an immune response and helped them produce antibodies, while preventing organs from damage.

Gizbert explained that while the number of monkeys was relatively small, the study was statistically powerful because they were exposed to an extremely high dose of the virus, which was about 5,000 times the deadly dose for humans. This reduced the need for extra control monkeys and restricted the unnecessary deaths of animals.

The researcher, who has worked on Ebola since the 1980s, says one of the most exciting aspects of Abdulzir was its extensive protection compared to antibody therapies, which only works against the Ebola Zairi species. “This is a big advantage,” says Gizbert.

Giliad Pharmaceutical Company is currently advancing clinical trials to the second phase of Marburg. The virus, one of Ebola’s close relatives.

Gizbert also emphasized the importance of financing by the US National Health Institute.

He said: 5 % of the costs of all these drugs and vaccines made against Ebola and many of these strange pathways and agents are provided by the US government. I think the general public agree that we need treatments for Ebola.

The end of the message